Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
{{output}}
Introduction: In patients with myelodysplastic syndromes (MDS), anemia is prevalent affecting 80%-85% of low-risk (LR-MDS) patients, with 40% eventually requiring red blood cell (RBC) transfusions. Except forlenalidomide, exclusi... ...
